The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 22, 2010
Filed:
Apr. 13, 2007
RU Chih C. Huang, Baltimore, MD (US);
Apostolos Gittis, Baltimore, MD (US);
Evangelos Moudrianakis, Baltimore, MD (US);
Julie A. Dohm, Oak Lawn, IL (US);
Jih RU Hwu, Hsinchu, TW;
Ming-hua Hsu, Hsinchu, TW;
Ru Chih C. Huang, Baltimore, MD (US);
Apostolos Gittis, Baltimore, MD (US);
Evangelos Moudrianakis, Baltimore, MD (US);
Julie A. Dohm, Oak Lawn, IL (US);
Jih Ru Hwu, Hsinchu, TW;
Ming-Hua Hsu, Hsinchu, TW;
Johns Hopkins University, Baltimore, MD (US);
Abstract
Reaction of nordihydroguaiaretic acid with various alkyl chlorides, 1-piperidinecarbonyl chloride, methyl chloroformate, or 1,1'-carbonyldiimidazole under alkaline conditions produced the corresponding phenol ethers, carbamates and carbonates, respectively, in 67-83% yields (Scheme 1 and Scheme 2). Among these derivatives, the nitrogen-containing compounds were converted to the corresponding hydrochloride salts. Having good solubility, these NDGA derivatives were found to be stable in aqueous solution. These new compounds exerted potent activities against HIV Tat-regulated transactivation in cos-7 cells. The most active transcription inhibitor compound of this series 5b (PN, Tetrapiperidino NDGA, meso-2,3-dimethyl-1,4-bis(3,4-[2-(piperidino)ethoxyphenyl])butane tetrakishydrochloride salt) has an ICof 0.88 μ